Skip to main content

IPO Chilli Ratings

IPO Chilli Ratings
Click to understand how it works

Featured

Food Innovators Holding Limited

Food Innovators Holdings Limited ("FIH" or the "Company") is offering 14m shares at $0.22 each, for which 13m shares will be through placement and the remaining 1m shares via a Public Offer. The IPO will close on 14 Nov at 12 noon and starts trading on 16 Oct 9am.  FIH has two business models - the first is to be a master lease and sublease the space to other tenants and the second is to operate and manage restaurants.  The Company currently has 12 restaurants in Japan, 10 in Singapore and 4 in Malaysia. The market cap based on the IPO price is around $24.9m. Financial Highlights FIH's revenue grew from $37.8m in FY2022 to $43.8m in FY2024. It is quite funny to see that being a master land lease holder has a higher margin than operating the restaurants, once again illustrating the point that it is better to be a landlord to shake leg and collect rent. According to the prospectus, the PER is around 19x. The Company intends to pay 20% of its net profit after tax a

Parkway Holdings (Kim Eng initiates Buy with $3.24 PT)

Event
Kim Eng is initiating coverage on Parkway with a Buy recommendation and a $3.24 price target. You can access the full report here.

Our Take

Miles ahead of its competitors
Parkway is the "de facto" standard for highly complex medical procedures, and a class above its peers. We are excited about their upcoming Novena hospital as it is setting itself miles ahead of its competitors. We are also looking forward to its exciting growth tragectory through the rapid expansion of its hospital operations in Asia.  At 13x FY10F PER (including gains from sale of 1/3 of medical suites at Novena), Parkway is still trading close to 'crisis-level' valuations. 

Sale of medical suites poses as potentially strong catalysts
The strongest near term catalyst could come from the potential sale of 1/3 of its medical suites at the new and upcoming hospital at Novena. Parkway is preparing to launch them in 1Q10, at indicative selling price of $3500psf. Proceeds from the sale (~$200m) can be deployed towards reducing the Group's net gearing, which currently stands at 0.4x. Parkway is likely to be successful during the first launch due to the pent-up demand from doctors and recent transactions done at Farrer Park Mediplex (at $3000-3500 psf)

Action
We initiate coverage on Parkway with a target price of $3.24, based on a SOTP valuation. It has been a laggard in the recent rally. The timing is ripe for a strong entry now.  

Comments